Target intelligence / Profile preview

Low affinity immunoglobulin gamma Fc receptor IIa (CD32a) (CD32a)

Target
CD32a
Molecular classification
Receptor, Fc-gamma receptor, Immunoglobulin superfamily
01

Overview

Low affinity immunoglobulin gamma Fc receptor IIa (CD32a), encoded by the FCGR2A gene, is a cell surface glycoprotein that binds the Fc portion of IgG antibodies to initiate various immune responses (UniProt P12318). On plasmacytoid dendritic cells (pDCs), CD32a is the sole Fc gamma receptor expressed and plays a pivotal role in the pathogenesis of autoimmune diseases like Systemic Lupus Erythematosus (SLE) (PubMed: 15548671). It mediates the internalization of immune complexes containing self-nucleic acids, which then activate endosomal Toll-like receptors 7 and 9, leading to the massive production of Type I interferons (PubMed: 21355063). This pDC-IFN axis is a major driver of chronic inflammation and tissue damage in lupus. Consequently, CD32a is a significant therapeutic target for inhibiting the uptake of pathogenic immune complexes. However, a major challenge in targeting CD32a is its expression on platelets, where receptor cross-linking can trigger platelet activation and lead to serious side effects such as thrombocytopenia or thrombosis. Current research focuses on developing selective inhibitors or Fc-engineered antibodies that can modulate pDC activity while avoiding adverse effects on platelets.

Other names
Fc gamma receptor IIaFCGR2ACD32FCG2FCGR2IGFR2CDw32
02

Mechanism of action

Blockade of immune complex internalization to prevent endosomal TLR7/9 activation and subsequent Type I Interferon production.

03

Biological functions

Immune responseEndocytosisType I Interferon productionAntigen presentationTLR signaling
04

Disease associations

Systemic Lupus ErythematosusInflammationHeparin-induced thrombocytopeniaSjögren's syndrome
05

Safety considerations

ThrombocytopeniaPlatelet activationImpaired immune complex clearanceRisk of infection
06

Interacting drugs

Margetuximab

2 more in the full profile.

07

Biomarkers

Type I Interferon signatureAnti-dsDNA antibodiesFCGR2A H131R polymorphismpDC activation markers

Beyond the preview

Go deeper on Low affinity immunoglobulin gamma Fc receptor IIa (CD32a) (CD32a).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Low affinity immunoglobulin gamma Fc receptor IIa (CD32a) (CD32a).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call